Compare SCZM & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCZM | ABUS |
|---|---|---|
| Founded | N/A | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 929.6M |
| IPO Year | N/A | 2008 |
| Metric | SCZM | ABUS |
|---|---|---|
| Price | $9.09 | $4.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $5.00 |
| AVG Volume (30 Days) | 459.8K | ★ 1.9M |
| Earning Date | 05-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $79.38 | N/A |
| Revenue Next Year | N/A | $783.24 |
| P/E Ratio | $14.27 | ★ N/A |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $6.90 | $3.04 |
| 52 Week High | $17.65 | $5.10 |
| Indicator | SCZM | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 55.64 |
| Support Level | $7.17 | $4.19 |
| Resistance Level | $12.74 | $4.64 |
| Average True Range (ATR) | 0.64 | 0.19 |
| MACD | 0.27 | 0.03 |
| Stochastic Oscillator | 68.07 | 76.61 |
Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapan, and Corporate and Other activities. Key revenue is generated from Zimapan.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.